The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,788.50
Bid: 1,788.00
Ask: 1,788.50
Change: 32.50 (1.85%)
Spread: 0.50 (0.028%)
Open: 1,743.50
High: 1,789.50
Low: 1,740.50
Prev. Close: 1,756.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS: Evraz Up On USD375 Million Return To Shareholders

Wed, 01st Apr 2015 10:42

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Wednesday.
-------
FTSE 100 WINNERS
-------
Barclays, up 3.6% at 251.25 pence, Lloyds Banking Group, up 2.0% at 80.33p, and Royal Bank of Scotland Group up 2.1% at 347.2p. The banking stocks are reversing all the losses they made on Tuesday. Morgan Stanley lifted its price target for Barclays to 333.2 pence from 315.5p, reiterating its Overweight rating, while it also raised its RBS price target to 391.6p from 375p, keeping its Equal-Weight rating. Meanwhile, Jefferies upgraded Lloyds to Hold from Underperform, saying the group's premium valuation is now supported by a progressively rising dividend.

Royal Dutch Shell 'B', up 2.2%. Reuters reports the US government upheld a 2008 lease sale in the Chukchi Sea off Alaska, meaning Shell has moved closer to returning to exploration work in the region since it lost control of the Kulluk oil rig in 2012. The Interior's Bureau of Ocean Energy Management will now consider Shell's exploration plan and will perform an environmental assessment of it, which would take at least 30 days. But Shell, in anticipation of returning to the region, has already moved rigs to Alaska, Reuters said.

Glaxosmithkline, up 2.3% at 2,144.5p. Barclays raised its price target for the pharmaceutical company to 1,840p from 1,690p, keeping its Overweight recommendation.
-------
FTSE 100 LOSERS
-------
Kingfisher, down 2.0%. The shares of the DIY retailer are down after rising 4.4% to a nine-month high on Tuesday as it reported a drop in sales and profit for its last financial year which it blamed on a slower French market and the strength of sterling, but said the new CEO plans to organise the company "very differently" to create a unified business that will share IT systems and buying and stock inventory infrastructure. Meanwhile, Nomura has cut its price target for Kingfisher to 305p from 315p, retaining its Neutral recommendation.
-------
FTSE 250 WINNERS
-------
Evraz, up 6.5%. The steel miner said it will return USD375 million to its shareholders even though its pretax loss widened in 2014 on the back of a USD1.0 billion foreign exchange loss caused by the devaluation of the rouble, saying it has "improved business prospects" in 2015. Evraz reported a pretax loss of USD1.08 billion in 2014, compared with a USD637 million loss in 2013, on the back of the substantial foreign exchange loss and an impairment charge.

Firstgroup, up 4.4%. The transport company said its trading in the fourth quarter and whole of the financial year that ended on Tuesday was in line with its expectations, with good performances in its UK bus and rail operations. FirstGroup said its UK bus business is delivering volume growth and achieving a positive yield, and it has made progress on cost-cutting efforts within the division. Separately, Panmure Gordon upgraded the transport company to Buy from Hold, cutting its price target to 120p from 140p.
-------
AIM ALL-SHARE WINNERS
-------
CEB Resources, up 70%. The natural resources focused investment company said it has sold its remaining stake in Australian Securities Exchange-listed Balamara Resources. In October, CEB Resources sold a third of its shares in Balamara for AUD350,340. Wednesday it sold its remaining stake, selling 9.8 million shares for AUD178,108, representing a much lower price compared with the sale in October last year.

Daily Internet, up 12%. The hosting and cloud infrastructure company said its expects its results for the year to the end of March be significantly improved on the prior year. It expects revenue to be ahead of market expectations and expects earnings before interest, taxation, depreciation and amortisation to be "materially ahead" of market forecasts. The company also said its Netplan Internet Solutions Ltd business has a series of contracts worth a total of GBP565,000 with a global insurance company.
-------
AIM ALL-SHARE LOSERS
-------
Amerisur Resources, off 27%. The company said its reserves and resources for its exploration and production assets in Colombia and Paraguay fell following an independent reserves report undertaken by Petrotech Engineering. The report concluded that the company's proven gross field reserves was 16.2 million barrels of oil, down from 19.8 million barrels in 2013, whilst proven plus probable gross field reserves fell to 24.6 million barrels from 32.8 million barrels.

The Real Good Food, down 14%. The company said the fall in European Union sugar prices has meant trading in its Napier Brown and Garrett Ingredients businesses has been very difficult. Napier Brown returned to profit in the second half, it said, but remains behind expectations for the year. The company said the group outside of Napier and Garrett performed ahead of expectations, with its Renshaw and Haydens businesses both performing well.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.